Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Ivosidenib (Tibsovo) plus azacitidine received FDA approval for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) harboring 

 mutations who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

The expanded approval is supported by findings from the phase 3 AGILE trial, which showed that ivosidenib plus azacitidine significantly improved event-free survival (EFS) over azacitidine alone (HR, 0.35; 95% CI, 0.17-0.72; 2-sided 

 = .0038).2 The addition of ivosidenib also improved median overall survival (OS) compared with azacitidine alone, at 24.0 months (95% CI, 11.3-34.1) vs 7.9 months (95% CI, 4.1-11.3), respectively (HR, 0.44; 95% CI, 0.27-0.73; 

"Today's approval builds on the established body of evidence for [ivosidenib], which is now approved across multiple 

-mutated cancer types," David K. Lee, chief executive officer at Servier Pharmaceuticals, stated in a press release. "As a leader in oncology pioneering the science behind targeted IDH inhibition, we are proud to bring a new therapeutic option to the acute myeloid leukemia community and remain committed to pushing the boundaries of healthcare innovation in oncology and beyond."

The global, double-blind, placebo-controlled, phase 3 trial enrolled patients with a centrally confirmed diagnosis of previously untreated 

-mutated AML who were not eligible for intensive chemotherapy.

To participate, patients needed to be at least 18 years of age, had an ECOG performance status of 0 to 2, acceptable hepatic and renal function, and who did not receive prior treatment with an IDH1 inhibitor or hypomethylating agent for myelodysplastic syndrome.

Patients were not candidates to receive intensive chemotherapy if they were aged 75 years or older, and had 1 of the following conditions: an ECOG performance status of 2, a severe cardiac disorder, a severe pulmonary disorder, a creatinine clearance of less than 45 mL/min, or a bilirubin level greater than 1.5 times the upper limit of the normal range.

Study participants were administered ivosidenib at a once-daily dose of 500 mg (n = 72) or matched placebo (n = 74), in combination with azacitidine at 75 mg/m2 for 7 days as part of 28-day cycles. Stratification factors included geographic region and disease status (primary vs secondary disease).

Treatment was given for a minimum of 6 cycles unless relapse, progressive disease, intolerable toxicity, or death occurred.

The primary end point was EFS, and secondary end points included complete remission (CR), OS, CR or CR with partial hematologic recovery, objective response, safety, and health-related quality of life.

The demographic and clinical characteristics of the patients at baseline were comparable across the arms. Of those in the investigative arm, 75% had primary AML and 25% had secondary AML; these rates were 72% and 28%, respectively, in the control arm. Moreover, 22% of those who received ivosidenib in combination with azacitidine had poor-risk cytogenetic characteristics vs 27% of those who received azacitidine alone.

A total of 39 patients were receiving treatment at the data-cutoff date of March 18, 2021; 38% of these patients were in the investigative arm and 16% were in the control arm.

 showed that CR was achieved by 47% (95% CI, 35%-59%) of those in the ivosidenib arm and 15% (95% CI, 8%-25%) of those in the azacitidine-alone arm (

 < .001). The median duration of CR was not yet reached with ivosidenib vs 11.2 months in those who received azacitidine alone.

In those who achieved a CR, the estimated probability that a patient would remain in CR at 1 year was 88% vs 36% in the investigative and control arms, respectively. The median time to CR was 4.3 months (range, 1.7-9.2) in the ivosidenib/azacitidine arm and 3.8 months (range, 1.9-8.5) in the azacitidine-alone arm. CR or CR with partial hematologic recovery was observed in 53% (95% CI, 41%-65%) and 18% (95% CI, 10%-28%) of those in the investigative and control arms, respectively.

Moreover, 62% (95% CI, 50%-74%) of those who received ivosidenib/azacitidine experienced an objective response vs 19% (95% CI, 11%-30%) of those who received azacitidine alone (

 < .001). The median duration of response was 22.1 months (95% CI, 13.0–not estimable) and 9.2 months (95% CI, 6.6-14.1), respectively.

The safety profile of the combination proved to be consistent with previously published findings. The most common toxicities that were observed in patients with newly diagnosed AML who received the regimen included nausea, vomiting, electrocardiogram QT prolonged, insomnia, differentiation syndrome, leukocytosis, hematoma, hypertension, arthralgia, dyspnea, and headache.

The select laboratory abnormalities that were experienced include decreased leukocytes, platelets, hemoglobin, neutrophils, phosphate, and magnesium, as well as increased lymphocytes, aspartate aminotransferase, alkaline phosphatase, and potassium.

Servier announces FDA approval of Tibsovo (ivosidenib tablets) in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia. News release. Servier Pharmaceuticals. May 25, 2022. Accessed May 25, 2022. https://prn.to/3sX1OOw

Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in 

. 2022;386(16):1519-1531. doi:10.1056/NEJMoa2117344

Articles

Ivosidenib plus azacitidine received FDA approval for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) harboring IDH1 mutations.

FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations

Lindsay Fischer is the Associate Editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

An effective approach to improving nurse responsiveness on an inpatient oncology unit may be through a dot-centered hourly rounding column, according to findings presented at the 47th Annual Oncology Nursing Society Congress.

This hourly rounding column, which was rolled-out at Smilow Cancer Hospital at Yale New Haven, was designed in consideration of RNs’ and personal care assistants’ (PCA) preexisting workloads. The innovation does not add documentation to their workflow but rather makes preexisting data points more visible.

“We saw an increase on all 4 units in nurse responsiveness, simply by highlighting

how frequently a nurse and patient care associate patient load is seen within the hour,” lead study author Brianna Lutz, MSN, RN, OCN, said in an interview with 

Built into the patient list in EPIC, the flowchart uses colored dots to show which patients have been attended to in the past hour. A green dot indicates that patients have been attended to within the past hour, while a red dot indicates that it has been over 1 hour since they received nurse attention.

When conducting rounds, if a nurse documents on any of the following data points, the dot automatically turns green: vital signs, pain assessment intake/output, fall risk interventions, activity, ambulation, hygiene, positioning and Medical Administration Records documentation. A red dot immediately prompts the RN or PCA to conduct a targeted hourly round immediately.

For this implementation, targeted hourly rounding includes screening of a patient’s pain, position, proximity to personal items, toileting needs, and preferences, and is conducted by either a registered nurse or patient care association. Targeted hourly rounding is critical to both patient safety and patient experience. The Press Ganey was chosen as a metric of targeted hourly rounding since it measures performance of quality care using the indicator “Response of Hospital Staff.”

As of February 2021, all 4 involved units (hematology, medical oncology, women’s health, and surgery) experienced an increased in the monthly average responsiveness score after implementation of the hourly rounding column. The average monthly “N” for each unit, according to Press Ganey data, were 3.5 (hematology), 4.8 (medical oncology), 45.3 (women’s health) and 53.6(surgery). In addition, staff have expressed satisfaction with the system and appreciate for the ability to visualize hourly rounding status and streamlined documentation.

“Historically, we have 4 separate siloed units. Historically, their first Ganey scores for responsiveness are on the lower side,” Lutz explained. “However, by implementing the hourly rounding column, we were able to have a real time visualization of the number of times that nurses and our patient care associates were in the room every hour without adding any burden to their workflow.”

Of note, the team created an instructional video explaining the rationale and goal of the implementation staff so they would understand that this was not a punitive action.

“The video was crucial, because we actually did see that some nurses in inpatient units felt like [this intervention] was a little bit punitive,” Lutz said.

“[They worried] that if their nurse leader saw that 3 out of 4 of their patients were red [dots], that they were in trouble or that they were lagging behind in their workflow,” she added. “We showed that video at safety huddles, and staff meetings across the 4 inpatient units. That small group of us who had worked on the project [shared the video] with the end users, so we did not have to rely on a middleman to the purpose and the intention. That was very important.”

Thus far, feedback has been positive, she added. Moving forward, broader implementation of this system may be appropriate across more units and systems.

“Our team of the oncology cluster and our EPIC analysts were really crucial and working collaboratively with kind of all of those key stakeholders was really helpful,” she said. “We are working now to roll this out beyond the oncology service line; it really has utility for all patient care levels and doesn't need to be siloed just to oncology.”

Lutz B, Crouch L, Sanchis D. Improving nurse responsiveness on inpatient oncology units. Presented at: 47th Annual Oncology Nursing Society Congress; April 27-May 1, 2022; Anaheim, CA. Abstract 220.

An hourly rounding column helped make integrated data points more visible and improve nurse responsiveness on an inpatient floor. 

How to Improve Nurse Responsiveness on an Inpatient Oncology Unit 

No matter the history of local therapy with radiotherapy (RT) or radical prostatectomy (RP), patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) achieved an overall survival (OS) benefit and improved prostate-specific antigen (PSA) outcomes with darolutamide (Nubeqa), according to a post-hoc analysis of the phase 3 ARAMIS trial (NCT02200614).

The findings, presented at the 2022 American Urological Association Annual Meeting, showed that the safety and tolerability of darolutamide in patients with nmCRPC were also consistent between patients who received prior local therapy compared with those who did not.

Previously, results from the planned primary analysis of the study showed that darolutamide significantly prolonged metastasis-free survival (MFS) compared with placebo in men with nmCRPC with no added toxicity. In a population of 1509 patients, the median MFS was 40.4 months with darolutamide vs 18.4 months with placebo (HR, 0.41; 95% CI, 0.34-0.50; 

< .001), resulting in a 31[LA1] % reduction in the risk of metastasis or death. Findings also trended in favor of the darolutamide arm across all secondary end points, including overall survival, time to pain progression, time to cytotoxic chemotherapy, and time to a symptomatic skeletal event.

The safety profile of darolutamide has been consistently favorable.1 In the primary analysis, treatment discontinuation occurred in 8.9% of the darolutamide group compared with 8.7% of the placebo arm. Overall, the rates of adverse events (AEs) were similar between the 2 arms, but darolutamide was associated with a higher incidence of seizures, falls, fractures, cognitive disorder, or hypertension vs placebo.

Long-term follow-up in the ARAMIS study lasted for 3 years. Patients with nmCRPC were randomized 2:1 in the study to receive either darolutamide 600 mg twice daily or placebo while continuing androgen-deprivation therapy (ADT). The long-term analysis assessed the secondary study end points of OS, PSA outcomes, and AEs in the patients who received prior local therapy of RP or RT to the primary tumor vs those who received neither therapy.

The 3-year survival and median time to PSA progression were estimated using Cox regression analyses, which were adjusted for age, baseline ECOG performance status, Gleason score, and time to diagnosis. The study investigators defined PSA response as a ≥ 50% decline from baseline (PSA50). AEs were summarized across the subgroups of patients who had prior RP (n = 239), RT (n = 177), either RP or RT (n = 416), neither RP nor RT (n = 538), and all patients treated with darolutamide (n = 954) in ARAMIS.

Overall, 43.6% of darolutamide-treated patients had received prior RP or RT. At baseline, the median age of patients across the subgroups ranged from 72.0 years to 76.0 years. The median PSA level in patients previously treated with RP was 6.2 ng/mL (range, 1.8-132.8), and the median PSA doubling time was 4.1 months (range, 0.7-10.4) in the RP or RT subgroup, 4.7 months (range, 1.0-11) in the neither RP or RT subgroup, and 4.4 months (range, 0.7-11.0) in all darolutamide-treated patients.

The majority of patients in the study had an ECOG performance status of 0 rather than 1 and a Gleason score ≥ 7 rather than < 7. The time from initial diagnosis to treatment in the study ranged from 74.5 months to 107.9 months.

In the darolutamide-treated population, the median OS was not reached across any subgroups or in the overall population. Among patients who received prior RP, the 3-year survival rate was 89.6%. Those treated previously with RT was a 3-year survival rate of 83.3%. Those treated with RP or RT and those who received neither had a 3-year survival rate of 86.9% and 79.0%, respectively. In all darolutamide-treated patients, the 3-year survival rate was 82.6%. In comparison, patients given placebo had a 3-year survival rate of 77.0%.

Results also showed that regardless of prior therapy, the median time to PSA progression was similar across subgroups and showed consistency with the overall ARAMIS patient population. Contrarily, the median time to PSA progression was 7.2 months in the placebo arm.

Specifically, in patients previously treated with RP (n = 239), the median time to PSA progression was 29.6 months. Those previously treated with RT (n = 177) had a 29.5-month median time to PSA progression. Among those who were previously treated with RP or RT (n = 416), the median time to PSA progression was 29.5 months, and those who received neither form of prior therapy (n = 538) had a median time to PSA progression of 26.0 months. In all darolutamide-treated patients (n = 954), the median time to PSA progression was 29.5 months.

In terms of PSA50, response rates were similar for darolutamide-treated patients regardless of their prior therapy subgroup. PSA50 responses across the prior therapy subgroups were also consistent with the overall darolutamide-treated arm in the ARAMIS trial. In the placebo arm, 33.0% achieved PSA50 response.

Patients who were treated with RP before darolutamide had an 85.8% PSA50 response rate compared with 85.3% for those treated with RT, 85.6% for those treated with RP or RT, 83.8% for those who had neither prior therapy, and 84.6% in the all darolutamide-treated patient population.

The safety profile observed with darolutamide in the longer-term analysis was consistent across all prior therapy subgroups. Overall, AEs were observed in 86.6% of the RP subgroup, 89.3% of the RT subgroup, 87.7% of the RP or RT subgroup, 84.2% of the group who receive neither RP or RT, and 85.7% of the all the darolutamide population. More than 20% of patients in each subgroup experienced grade 3 or higher AEs.

Common AEs observed during the study included fatigue, hypertension, bone fracture, falls, rash, and mental impairment. These AEs were determined to be events that are commonly observed with androgen receptor inhibitors. Local AEs that occurred in > 5% of any subgroup included fatigue, constipation, abnormally frequent urination, hematuria, and dysuria.

Siemens DR, Fizazi K, Shore ND, et al. Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer patients with and without prior local therapy with radical prostatectomy or radiotherapy. 

. 2020;207(5):e451. doi:10.1097/JU.0000000000002570.05

Fizazi K, Shore N, Tammela TL, et al; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. 

. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

Darolutamide significantly prolonged metastasis-free survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer with no added toxicity.

Darolutamide Extends Survival in nmCRPC Regardless of Prior RT or Radical Prostatectomy 

Dr. Jackson is a certified oncology and bone marrow transplant clinical nurse specialist with clinical expertise in hematology/stem cell transplantation/cellular therapy. She is currently unit director–providing oversight of the clinical and fiscal operations of an inpatient hematology unit. Dr. Jackson is also a member of the National Association of Clinical Nurse Specialist, American Asociation of California Nurse Leaders, and the Oncology Nurses Society.

The use of a discharge lounge for patients undergoing stem cell transplant may prove an effective and safe strategy for facilitating swifter discharge and preventing bottlenecking, according to Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN.

Jackson served as an investigator on a poster presentation regarding the utility of such a discharge lounge that was recently presented at the 47th Annual ONS Congress. In an interview with 

®, she highlights the significance of this intervention and its potential to ease the burden for night shift nurses.

Historically, these patients were not always able to use the discharge lounge because of neutropenia and immunosuppression concerns, she explains. However, during COVID-19, it became a priority to help patients discharge as swiftly as possible to reduce their time in the hospital and increased risk of infection.

Through the collaboration between the Observational Unit Discharge Lounge and Oncology/SCT Unit, this ongoing project has demonstrated that this innovation may result in earlier bed availability for patients being admitted later in the day or in the evening.

Videos

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses how collaboration between an oncology unit and discharge lounge can improve discharge times for patients who have undergone stem cell transplantation.  

Stephanie Jackson Discusses the Feasibility of a Discharge Lounge for Stem Cell Transplant Units

Oncology providers can implement strategies to help improve colorectal cancer [CRC] screening rates among their patients, according to Denalee O'Malley, PhD. Structural racism, income inequality, and geographic barriers can all affect screening access, however, leveraging the provision of resources and support available to qualified health centers can be useful in combatting these barriers.

“The barriers are multilevel, but most of them can be resolved with additional resources. At the patient level, there are [barriers to] transportation, time off work, and access to appointments,” O’Malley, an assistant professor of family medicine and community health at Rutgers Robert Wood Johnson Medical School, said interview with 

®. “The centers at the clinic sites need test kits to be able to send to patients for first-line screening. They need personnel to prepare and mail them, postage, staff time to follow-up and coordinate both the abnormal and the positive results, and they need to [be able to] support patients in the transition to oncology [care].”

One strategy that is being used to improve screening rates in underserved communities is through programs such as ScreenNJ, which partners with community organizations, federally qualified health centers, and others to improve outreach and community education, support provider awareness, and strengthen peer support/patient navigation programming.

In the interview, O'Malley, who is also a member of the Cancer Prevention and Control Program and a research member of the Cancer Health Equity Center of Excellence at Rutgers Cancer Institute of New Jersey, shed light on racial and ethnic disparities in CRC screening, and strategies that can be used to address existing barriers in the clinic and beyond.

®: Please discuss the research you are currently conducting in the realm of racial disparities in CRC screening and care.

: I am currently working on a project funded by the National Cancer Institute called “Optimizing CRC Screening Among Patients with Diabetes in Safety-Net Primary Care Settings,” to target implementation approaches. This study examines differences in the types of CRC screenings utilized by patients who receive most of their care in the community health-center system, which is the primary care safety net.

The goal is to identify and overcome barriers at multiple levels—the patient, the clinic, and the health system—that can all affect optimal use of CRC screening tests, and then develop strategies that can be implemented based on context-specific needs of clinics.

How can racial disparities affect CRC screening? What are some existing barriers to testing and appropriate care?

There is structural racism embedded in the health care delivery system, and the disparities that affect CRC screening are intersectional. Racism, income inequality, geographic disparities, and how healthcare is organized and delivered all have an effect on CRC screening and care.

Multiple types of CRC screening tests [exist], which makes [this] more complicated, and they have different levels of efficacy and [need to be performed in] different intervals. For example, a FIT test needs to be administered every year. A colonoscopy, if the test comes back normal, has a 10-year interval, based on the current guidelines.

Community health centers are considered the primary care safety net. A little over 20% of community health center patient populations are uninsured, and the largest payer nationally in the community health setting is Medicaid.

When you use a first-line FIT test, there are multiple steps between an abnormal FIT test and a cancer diagnosis and transition to care. There is the screening itself, the cancer detection, the pathology report, and then, the transition to a cancer center or an oncologist. Barriers at the patient level can include not having a reliable telephone to get the [test result] information [returned to them], not being able to take off work to get a colonoscopy if the test is found to be abnormal, the inability to get an appointment that accommodates their schedule, and the need to get transportation if anesthesia is involved.

At the health-system level, there can be an insufficient number of specialists who offer the diagnostic tests at different centers. There can be there can be any constellation of these problems. In the study focused on patients with diabetes, there is also a cumulative risk involved with having another medical condition. Patients who have diabetes have a 27% greater lifetime risk of having CRC. Diabetes disproportionately affects the Hispanic and African American population, and in the in the community health center setting, we see a much larger proportion of uncontrolled diabetes than you would in a traditional primary care setting. What that means in the care space is that if a patient comes in with an acute health need, preventative health needs might take a backseat.

How can some of these barriers be addressed?

Within the medical neighborhood, the resources that the clinics need [include] receptive diagnostic centers and oncology colleagues who they can transition patients to who are in need diagnostic workups or cancer care.

What strategies are needed to help improve CRC screening in high-priority populations to prevent loss of life?

These are contextually bound strategies. The answer lies in partnering with different types of community health centers, seeing what the barriers are, and coming up with strategies that fit the needs of the context. This requires a partnership between researchers, community members, community health-center staff, and clinicians who are the experts on how their organization operates and the barriers that they face.

How can your colleagues in the community work to better address existing disparities to help close the gap?

Awareness about prevention and clear messaging is important. We are living in a time where misinformation is abundantly available. [Ensuring] that we have outlets in the community that can provide patients with reliable information about the benefits of screening is important.

[We also need] to develop creative solutions, based in the community, for the barriers that [these] populations face. [Some of these] can be universal; we [may] see [some of them] across different sites, but others may be different. Some places have an environment that has better transportation, so that may not be an issue in 1 place and a huge barrier in another.

The other piece is to be more mindful about what we accept as a normal course of business and interrogate why we do things the way we do them. [We need to ask ourselves, who] is this intervention benefiting and who is it potentially leaving out? Those are ways that we can do a better job at closing that gap.

How pivotal is screening in terms of diagnosis and outcomes in CRC?

With most prevention, the famous slogan to follow is, “An ounce of prevention is worth a pound of cure.” CRC is a clear example of that. If CRC was prevented, such as removing a polyp [prior to diagnosis], the potential life saved would be 6.5 years on average. The main takeaway is that [screening and treatment of CRC] is all connected. Our primary care system and its strength affect what we see later down the road in cancer care.

This is all connected in the sense that a patient who comes in for cancer care comes as a whole person who has other illnesses. Since cancer is generally a condition of the aging, chances of someone coming to a cancer diagnosis with chronic illness matters and affects that journey. We need to be intentional about that earlier in the care pathway because we could be more intentional about preventing what can be more cumulative risks as someone lives longer.

Exploring racial and ethnic disparities in colorectal cancer screening. Rutgers Cancer Institute of New Jersey. March 1, 2022. Accessed May 19, 2022. 

This article was originally published on 

 as “Addressing Barriers Contributing to Disparities in CRC Screening in Underserved Populations.”

Strategies to combat ethnic disparities in colorectal cancer screening are not limited to the clinic.  

How Oncology Providers Can Help Mitigate CRC Screening Disparities 

Azacitidine (Vidaza) is now FDA approved for pediatric patients with newly diagnosed myelomonocytic leukemia.

FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia

Current ASCO guidelines recommend that providers discuss the possibility of infertility with their patients as soon as possible before treatment begins. 

GnRH Agonists Demonstrate Utility in Preventing Premature Menopause in Women With Breast Cancer

Investigators reported that 33% of patients receiving dabrafenib plus trametinib for BRAF V600E–mutated glioma responded to treatment, including 3 complete responses and 12 partial responses.

Dabrafenib/Trametinib Elicits Viable Phase 2 Responses in BRAF V600E–Mutated Glioma

A medication extension set may be the preferred method for subcutaneous hyaluronidase injections compared with a traditional needle. 

Medication Extension Set Makes Subcutaneous Hyaluronidase Injections Easier, More Comfortable in Cancer Treatment

An expert with the phase 1b TRIMM-2 trial underscores the significance and findings for patients with multiple myeloma. 

Heavily Pretreated Patients With Relapsed/Refractory Myeloma Achieve Encouraging Responses With Teclistamab Plus Daratumumab 

Michelle Mollica, PhD, MPH, RN, OCN, senior advisor in the NCI Office of Cancer Survivorship, discusses different long-term care considerations for nurses caring for patients with cancer. 

Oncology Nurses Play Pivotal Role in Survivor Follow-Up Care

The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations

Brianna Lutz, MSN, RN, OCN, discusses a red-and-green dot hourly column that shows which patients with cancer have been attended to in the past hour. 

Brianna Lutz on How to Improve Nurse Responsiveness on an Inpatient Oncology Unit

Liz Stokes, PhD, JD, RN, director of the Center for Ethics and Human Rights, discusses the nurse’s role in medical aid in dying and common misconceptions.

ANA Releases New Survey Findings on Nurse Positions on Medical Aid in Dying

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated a manageable toxicity profile for patients with advanced prostate cancer. 

Patients With Advanced Prostate Cancer on Relugolix Experience Manageable Toxicity Levels 

Patricia Jakel, RN, MN, AOCN, discusses burnout and compassion fatigue in acute oncology care.

Patricia Jakel Comments on Combating Burnout in the Acute Care Setting

In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival. 

Patients With Metastatic Urothelial Carcinoma Achieve Superior Survival After Experiencing irAEs With Pembrolizumab

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy. 

Regardless of Prior Local Treatment, Patients With mHSPC Achieve Improved Long-Term Survival With Enzalutamide Plus ADT

Patients with locally advanced muscle invasive bladder cancer may experience superior benefit from gemcitabine and carboplatin if the chemotherapy is co-administered with vitamin c. 

Vitamin C Increases Chemotherapy Responses in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer

Podcasts

Loyda E. Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, highlights nursing considerations in prescribing and administering endocrine therapy to patients with HR+ breast cancer. 

Top Medical News

FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations

How to Improve Nurse Responsiveness on an Inpatient Oncology Unit

Darolutamide Extends Survival in nmCRPC Regardless of Prior RT or Radical Prostatectomy

Stephanie Jackson Discusses the Feasibility of a Discharge Lounge for Stem Cell Transplant Units

How Oncology Providers Can Help Mitigate CRC Screening Disparities

Most Recent